Latest News

The decision is based on phase 3 DESTINY-Breast11 trial data, in which the investigational regimen displayed improved pCR vs SOC in this breast population.
Trastuzumab Deruxtecan Regimen Accepted for Review in HER2+ Breast Cancer

October 2nd 2025

The decision is based on phase 3 DESTINY-Breast11 trial data, in which the investigational regimen displayed improved pCR vs SOC in this breast cancer population.

ETX-636’s selectivity may reduce the risk for hyperglycemia and other wildtype PI3Kα-related AEs vs other non-mutant selective PI3Kα inhibitors.
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer

October 2nd 2025

In the phase 3 EMBER-3 trial, Guardant360 CDx was used to identify patients with ESR1-mutated advanced breast cancer who may benefit from imlunestrant.
Companion Diagnostic Earns FDA Approval for Imlunestrant in Breast Cancer

October 1st 2025

Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer
Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer

September 30th 2025

T-DXd demonstrated a safety profile consistent with previously reported analyses.
T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup

September 29th 2025

Video Series
Video Interviews
Podcasts
Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Latest CME Events & Activities

More News